Imipenem + Cilastatin

DRUG3 trials

Sponsors

Merck Sharp & Dohme LLC, Vancouver Coastal Health, The University of Queensland

Conditions

Infectious DiseaseMycobacterium Abscessus InfectionMycobacterium Abscessus Pulmonary DiseaseNon-Tuberculous Mycobacteria Pulmonary DiseaseNon-Tuberculous Mycobacterial (NTM) InfectionsNon-Tuberculous Mycobacterial (NTM) Pneumonia

Phase 1

A Single-Dose Study to Investigate the Pharmacokinetics of MK-7655 in Participants With Impaired Renal Function (MK-7655-005)

CompletedNCT01275170

Merck Sharp & Dohme LLCInfectious Disease

Start: 2011-01-28End: 2012-03-05Updated: 2020-06-11

Bacteriophage Therapy for Mycobacterium Abscessus Pulmonary Infection

Enrolling by invitationNCT07228702

Vancouver Coastal HealthMycobacterium Abscessus Infection, Non-Tuberculous Mycobacterial (NTM) Pneumonia

Start: 2026-01-11End: 2027-10-01Target: 1Updated: 2026-06-03

Phase 2

Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial

Not yet recruitingNCT07485010

The University of QueenslandMycobacterium Abscessus Infection, Mycobacterium Abscessus Pulmonary Disease, Non-Tuberculous Mycobacterial (NTM) Infections +1

Start: 2027-04-01End: 2031-07-01Target: 300Updated: 2026-03-20